4.5 Review

Inherited eye-related disorders due to mitochondrial dysfunction

期刊

HUMAN MOLECULAR GENETICS
卷 26, 期 R1, 页码 R12-R20

出版社

OXFORD UNIV PRESS
DOI: 10.1093/hmg/ddx182

关键词

-

资金

  1. Medical Research Council (UK)
  2. Fight for Sight (UK)
  3. UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration
  4. NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust
  5. UCL Institute of Ophthalmology
  6. Department of Ophthalmology, Emory University School of Medicine from Research to Prevent Blindness, Inc. (New York, N.Y.)
  7. NIH/NEI (Department of Ophthalmology, Emory University School of Medicine) [P30-EY06360]
  8. MRC [G0701386, G1002570] Funding Source: UKRI
  9. Fight for Sight [1479/80, 1570/1571] Funding Source: researchfish
  10. Medical Research Council [G1002570, G0701386] Funding Source: researchfish

向作者/读者索取更多资源

Genetic disorders due to mitochondrial dysfunction are not uncommon and the majority of these patients will have eye-related manifestations, including visual loss from the optic nerve and retinal disease, visual field loss from retrochiasmal visual pathway damage, and ptosis and ocular dysmotility from extraocular muscle involvement. Defects in both the nuclear and mitochondrial genomes cause mitochondrial dysfunction via several mechanisms, including impaired mitochondrial energy production, oxidative stress, mitochondrial DNA instability, abnormalities in the regulation of mitochondrial dynamics and mitochondrial quality control, and disturbed cellular interorganellar communication. Advances in our understanding of the molecular genetic basis of mitochondrial disease have not only improved genetic diagnosis, but they have provided important insights into the pathophysiologic basis of these disorders and potential therapeutic targets. In parallel, more sophisticated techniques for genetic manipulation are facilitating the development of animal and in vitro models that should prove powerful and versatile tools for disease modelling and therapeutic experimentation. Effective therapies for mitochondrial disorders are beginning to translate from bench to bedside along the paths of neuroprotection, gene replacement and stem cell-based regenerative paradigms. Additionally, preventing the transmission of pathogenic mtDNA mutations from mother to child is now a reality with in vitro fertilization mitochondrial replacement techniques.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据